Journal Home
Search for

Volume 20, Issue 2, Supplement, Page S34 (February 2009)


View previous. 107 of 402 View next.

Abstract No. 85: BeadBlock, Embospheres and PVA Particles: Is There a Difference in Clinical and Imaging Outcomes After Uterine Fibroid Embolization?

J.V. Liaw*,1, C. Yun1, S.P. Kalva13, T.G. Walker13, J.M. Kickham23, A. Goodman23, S. Wicky13, B. Janne d'Othee13

Article Outline

Purpose

Materials & Methods

Results

Conclusion

Copyright

Purpose 

return to Article Outline

To compare clinical and imaging outcomes after uterine fibroid embolization (UFE) with BeadBlock, Embospheres and polyvinyl alcohol (PVA) particles.

Materials & Methods 

return to Article Outline

In a retrospective study of all our patients who underwent UFE from 08/2000 to 08/2008, we reviewed the electronic medical records, MRI and angiographic images (pre/post UFE), procedural parameters, and follow-up clinical data at 2 weeks, 3 months, 6 months, and 1 year. Symptoms were divided into pain/pressure, bleeding, or combined. Fibroids were classified as localized (submucosal, intramural, subserosal, or combined) vs diffuse. Fibroid volume was calculated by the largest diameter in 3 anatomic planes. Particle size ranged from 300-500 to 710-1000 microns. Angiographic endpoint was stasis or near-stasis.

Results 

return to Article Outline

179 consecutive women had UFE with BeadBlock (n=31), Embospheres (n=78) or PVA (n=70). The PVA group was older (mean = 47 vs 43 vs 43 years, p=0.004) and presented more often with combined symptoms (p=0.025). Fibroid location (localized vs diffuse), side (right vs left), maximal uterine diameter, and side of larger uterine artery were similar (p>0.05). The largest fibroid in BeadBlock patients was significantly smaller (mean diameter = 6.0 cm) than in PVA (7.7 cm) or Embospheres patients (9.8 cm). Similar angiographic endpoints were observed across groups (86% near-stasis) and were reached after injecting 4 syringes or less in 61% of BeadBlock, 55% of Embospheres and 87% of PVA cases (p=0.008); cost difference of all agents in our institution fell within a $50 range. During follow-up, all but 2 patients experienced symptomatic improvement and normalization of menses. None had symptoms of infection or persistent facial flushing. On MRI, the largest uterine and fibroid diameters, percentage of fibroid infarction, and residual enhancement rate were similar in all groups, with no myometrial infarction. Despite baseline differences in largest fibroid diameter, the calculated mean volume reduction after UFE was similar in all groups (41% BeadBlock, 48% Embospheres, 40% PVA).

Conclusion 

return to Article Outline

UFE with all 3 particle types yielded similarly good clinical and imaging outcomes. No single agent demonstrated greater treatment efficacy.

1 Massachusetts General Hospital - Radiology, Boston, MA

2 Massachusetts General Hospital - Obstetrics and Gynecology, Boston, MA

3 Harvard Medical School, Boston, MA

PII: S1051-0443(08)01181-0

doi:10.1016/j.jvir.2008.12.075


View previous. 107 of 402 View next.